Sara Zaknoen

Adastra Pharmaceuticals, Inc. engages in the provision of clinical and commercial development of proprietary drugs for the treatment of various cancers. The company was founded by Tracy L. Parrott in 2005 and is headquartered in Princeton, NJ.

Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ.

The Western Pennsylvania Hospital provides clinical and health related services. The hospital offers emergency medicine, heart care, cancer treatment, orthopedics, and surgery services. It is affiliated with Clarion University, Indiana University of Pennsylvania, Pennsylvania State University, and Temple University. The Western Pennsylvania Hospital is founded in 1848 and is headquartered in Pittsburgh, PA.

Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA.

Part of CK Life Sciences International (Holdings), Inc., Polynoma LLC is an immuno-oncology focused biopharmaceutical company headquartered in San Diego, CA. Polynoma's lead asset is a novel polyvalent antigen vaccine, Seviprotimut-L, for the prevention of recurrence of melanoma. The vaccine has been safely administered in more than 1,000 patients. Polynoma is an immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. The company was founded by Paul A. Hopper.